

Curriculum Vitae

General Information

Name: Tomassetti Sara

Office Address:

Pulmonary Unit
 GB Morgagni Hospital
 Via C Forlanini 34
 47121 Forlì (FC)
 ITALY

Education

2000	MD, summa cum laude	Medical School (Prof G Marchesini)	Bologna University, Italy
------	------------------------	------------------------------------	------------------------------

Postdoctoral Training

2001-2004	Resident	Pulmonary Medicine (Prof LM Fabbri)	Modena University, Italy
03/2003-04/2004	Research Fellow	Respiratory and Crit Care Med (Prof. SD Shapiro)	Harvard Medical School, Brigham and Women's

			Hospital, Boston, MA, USA
2005-2006	Sub-investigator in clinical trial and honorary clinical activity	Interventional Pulmonary Unit (Prof. V Poletti)	GB Morgagni Hospital, Forlì, Italy
May 2008; Sept 2009; August 2010; August 2011, May 2012, Nov 2013, Aug 2015	Visiting Clinician Program	Respiratory and Crit Care Med (Prof. JH Ryu)	Mayo Clinic, Rochester USA

Appointments at Hospitals

2006- currently	Pulmonary Physician	Pulmonary Medicine Unit, Thoracic Department	GB Morgagni Hospital, Forlì, Italy
-----------------	---------------------	---	---------------------------------------

Other Professional Positions

2011-currently	Consultant	Intermune-Roche
01/2014-currently	PASSPORT Steering Committee Member	Intermune-Roche
10/2014-currently	Consultant	Boeringher-Inghelheim
15/6/2016-currently	Rapresentative Member	ERN-LUNG
04/2016-currently	member of the Global IPF Network	University of Colorado, USA

Professional Societies

2010- currently	European Respiratory Society	Member
2013- 2014	European Respiratory Society	ERS Evaluation Committee, Reviewer.
2010- currently	ERS – Interstitial Lung Disease Study group 1.5	Member

2012 - currently	AIPO – Ass Italiana Pneumologi Ospedalieri	Member
	AIPO – Ass Italiana Pneumologi Ospedalieri	Leader of the Interstitial Lung Diseases and Pulmonary Hypertension Study Group
10/2013-10/2017	Pneumologi Ospedalieri	

Major Administrative Leadership Positions

2009- 2014	Supervisor of IPF Clinic	Pulmonary Medicine Unit, GB Morgagni Hospital, Forli, Italy
2015- currently	Supervisor of ILD Clinic (AIMART)	Pulmonary Medicine Unit, GB Morgagni Hospital, Forli, Italy

Editorial Activities

2018-currently	Editor in Chief	Sarcoidosis Vascular and diffuse lung disease journal
2017-2018	Member of the Editorial Board and Reviewer	Sarcoidosis Vascular and diffuse lung disease journal
	Member of the Editorial Board and Reviewer	Rassegna di Patologia dell'Apparato Respiratorio
2012-currently	Reviewer	
2013	Reviewer	Human Immunology
2013-currently	Reviewer	BMC Pulmonary Medicine
2014-currently	Reviewer	Respirology
2014	Reviewer	Respiratory Research
2015-currently	Reviewer	European Resp Journal
2015	Reviewer	Case Report in Pulmonol.
2018	Reviewer	Journal Thoracic Disease
2018-currently	Reviewer	European Respiratory Review

Honors and Prizes

6-Dec- 2010	Robalo Cordero Award	26th Congress of Portugese Resp Soc, Coimbra, Portugal 6th International WASOG Conference in Paris	Research Project : “IPF: from environment to genetic” Poster title “The diagnostic role of TBLC in the MD of IPF”.
7-Jun-2013	Poster Award		Publication title “Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis” AJRCCM 2017
14-Feb-2018	Best publication 2018 Award	Area Vasta Romagna	

Grant Recipient

12/2017	Investigator Initiated Study (IIS) funded by Roche and AMMP (Ass Morgagni Mal Polmonari)	Title: 15 years of real life data to study the shifting mortality scenario of IPF Retrospective study evaluating factors that have impacted and changed IPF prognosis	Pricipal Investigator
---------	--	--	-----------------------

Report of Funded Projects

2005-2006	INSPIRE TRIAL NCT00075998 Sub-investigator
-----------	--

Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF

2006-
2009 CAPACITY TRIAL

NCT00287729

Sub-investigator

The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF) and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.

2008-
2009 BUILD 3 TRIAL

NCT00391443

Coordinator

BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.

2010 ARTEMIS-IPF

NCT00768300

Sub-investigator

Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

As top enrollers we were audited and successfully completed PPD audit on 16-17

November 2010.

2010 ARTEMIS-PH

NCT00879229

Sub-investigator

This Phase 3, randomized, double-blind, placebo-controlled, multicenter study will compare the efficacy and safety of ambrisentan to placebo in subjects with pulmonary hypertension associated with idiopathic pulmonary fibrosis

2010-
2011 RESOLVE

funded by the European
Commission under
FP7-HEALTH-F4-2008
Contract no. 202047

Study Review Board Member and Subinvestigator

The basis for all human studies is a combination of careful clinical assessment of disease conditions and sequential analysis of biological data – to identify relevant molecular targets and separate them from those connected to regular organ repair. Studies relate to lung manifestations of progressive fibrotic disorders of the lung such as IPF and other ILDs.

2011-2012 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

NCT01335464

Sub-investigator

The purpose of this trial is to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data.

2011-2014 Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Mechanism and Biomarkers.

E-Rare2 JTC 2011- Funded by European Commission

Sub-investigator

The purpose of this prospective study is to investigate clinical and biomolecular aspects of acute exacerbation of IPF

2012- currently ongoing An open label extension trial of the long term safety of oral BIBF 1120 patients with Idiopathic Pulmonary Fibrosis (IPF)

Principal Investigator

The primary objective of this study is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow-up period in the phase III trials 1199.32.

Efficacy and Safety of GS-6624 in subjects with Idiopathic Pulmonary Fibrosis (RAINIER)

GS – US – 322-0207

2013- 2016 **Principal Investigator**

A phase 2, randomized, double blind, Placebo – Controlled Multi centre study to assess the efficacy and safety of GS - 6624

Safety profile of Esbriet® inpatients with IPF and to monitor for any unknown or potential risks of treatment with Esbriet (PASSPORT)

2014 – 2016 PIPF 025

Sub – Investigator and Steering Committee Member

Post – Authorisation Safety Study of Esbriet (Pirfenidone), a prospective observational Registry to evaluate Long Term Safety in Real World Setting.

2014 - ongoing Efficacy and Safety of LEBRIKIZUMAB in patients with idiopathic pulmonary fibrosis GB28547

Principal Investigator

A phase II, randomized, double – blind, placebo controlled to assess the efficacy and safety

of Lebrikizumab in IPF

PROTOCOL NUMBER: GB28547

EUDRACT NUMBER: 2013-001163-24

2016-
currently
enrolling

"IPF Italian Observational Study (FIBRONET) " (Boehringer Ingelheim)

Principal Investigator

The primary objective of study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation. In particular, the study aims to provide information on disease characteristics and treatment modalities (at enrolment) and on disease progression.

PROTOCOL NUMBER 1199.262

2016-on
going

BIBF 1199.36 "A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment" (Boehringer Ingelheim)

Principal Investigator

The primary objective of study is evaluating the efficacy and safety of the combination treatment with nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis (IPF) with advanced impairment of lung function.

PROTOCOL NUMBER: 1199.36

EUDRACT NUMBER: 2015-002619-14

2016-on
going

ML39260 IRENE "An observational, retrospective, multicentre study to evaluate, the efficacy of Pirfenidone administered according to clinical practice to patients with idiopathic pulmonary fibrosis

Principal Investigator

The primary objective is aimed at observing retrospectively clinical progression, in term of lung function and physical endurance at 12 months from the start of treatment, in IPF patients treated with Pirfenidone in accordance with normal clinical practice, at Italian Pneumology centres with expertise in the management of this disease.

PROTOCOL NUMBER : ML39260

2016-on
going

MA29957 : “A phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of Sildenafil added to Pirfenidone in patients with advanced idiopathic pulmonary fibrosis and intermediate or high probability of group 3 pulmonary hypertension.

Principal Investigator

The primary efficacy objective for this study is to evaluate the efficacy of adding sildenafil compared with placebo to pirfenidone treatment in patients with advanced IPF and intermediate or high probability of Group 3 PH. The primary efficacy endpoint will be evaluated based on a comparison of the proportion of patients showing disease progression over 52 weeks of treatment period.

PROTOCOL NUMBER : MA29957

EUTRACT NUMBER : 2015-005131-40

2012-
currently
ongoing

An open label extension trial of the long term safety of oral BIBF 1120 patients with Idiopathic Pulmonary Fibrosis (IPF)

Principal Investigator

The primary objective of this study is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow-up period in the phase III trials 1199.32.

2013- 2016 Efficacy and Safety of GS-6624 in subjects with Idiopathic Pulmonary Fibrosis (RAINIER)

GS – US – 322-0207

Principal Investigator

A phase 2, randomized, double blind, Placebo – Controlled Multi centre study to assess the efficacy and safety of GS - 6624

2014 – Safety profile of Esbriet® inpatients with IPF and to monitor for any unknown or potential risks of treatment with Esbriet (PASSPORT)

2016 PIPF 025

Sub – Investigator and Steering Committee Member

Post – Authorisation Safety Study of Esbriet (Pirfenidone), a prospective observational Registry to evaluate Long Term Safety in Real World Setting.

2014 -
ongoing Efficacy and Safety of LEBRIKIZUMAB in patients with idiopathic pulmonary fibrosis
GB28547
Principal Investigator
A phase II, randomized, double – blind, placebo controlled to assess the efficacy and safety of Lebrikizumab in IPF

PROTOCOL NUMBER: GB28547

2016- currently enrolling EUDRACT NUMBER: 2013-001163-24

"IPF Italian Observational Study (FIBRONET) " (Boehringer Ingelheim)

Principal Investigator

2016-on going The primary objective of study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation. In particular, the study aims to provide information on disease characteristics and treatment modalities (at enrolment) and on disease progression.

PROTOCOL NUMBER 1199.262

BIBF 1199.36 "A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment" (Boehringer Ingelheim)

2016-on Principal Investigator
going

The primary objective of study is evaluating the efficacy and safety of the combination treatment with nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis (IPF) with advanced impairment of lung function.

PROTOCOL NUMBER: 1199.36

EUDRACT NUMBER: 2015-002619-14

2016-on ML39260 IRENE "An observational, retrospective, multicentre study to evaluate, the efficacy of Pirfenidone administered according to clinical practice to patients with idiopathic pulmonary fibrosis
going

Principal Investigator

The primary objective is aimed at observing retrospectively clinical progression, in term of lung function and physical endurance at 12 months from the start of treatment, in IPF patients treated with Pirfenidone in accordance with normal clinical practice, at Italian Pneumology centres with expertise in the management of this disease.

PROTOCOL NUMBER : ML39260

2017-on going MA29957 : “A phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of Sildenafil added to Pirfenidone in patients with advanced idiopathic pulmonary fibrosis and intermediate or high probability of group 3 pulmonary hypertension.

Principal Investigator

The primary efficacy objective for this study is to evaluate the efficacy of adding sildenafil compared with placebo to pirfenidone treatment in patients with advanced IPF and intermediate or high probability of Group 3 PH. The primary efficacy endpoint will be evaluated based on a comparison of the proportion of patients showing disease progression over 52 weeks of treatment period.

2017-on PROTOCOL NUMBER : MA29957

going EUTRACT NUMBER : 2015-005131-40

BIBF 1199.247 “A phase III trial on efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) (PF-ILD)”

Principal Investigator

The aim of the current study is to investigate the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD). Based on its efficacy and safety in Idiopathic Pulmonary Fibrosis (IPF), it is anticipated that Nintedanib will be a new treatment option for patients with PF-ILD.

ClinicalTrials.gov Identifier:NCT02999178

Sponsor: Boehringer

MA39189 "A phase III Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease"

Principal Investigator and National Coordinator

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).

ClinicalTrials.gov Identifier: NCT03099187

Sponsor: Roche

Report of the most relevant Unfunded Projects since 2010

2010 The diagnostic role of transbronchial biopsy in UIP

Retrospective, blinded

Principal Investigator

Approved Ethics Committee : 22/06/2010 Nr. 1493/2010

(Published)

2010

Pulmonary manifestations of Birt-Hogg-Dubè syndrome

Retrospective Study

Principal Investigator

Approved Ethics Committee : 25/08/2010 Nr. 2613/2010

(Published)

2010

Familial Interstitial Pneumonia Profile

Retrospective Study

Principal Investigator

Approved Ethics Committee : 26/08/2010 Nr. 2611/2010

(Published, Feb 2014)

2010

Anticoagulant therapy for Idiopathic Pulmonary Fibrosis

Retrospective Study

Principal Investigator

Approved Ethics Committee : 29/10/2010 Nr. 3327/2010

(Published)

2011

A simple, clinically relevant staging System for Idiopathic Pulmonary Fibrosis

Retrospective Study

Participating Centre

Approved Ethics Committee : 08/04/2011 Nr. 1385/2011

(Published)

2011

Is Medical Thoracoscopy indicated in the management of Multiloculated and Organized Thoracic Empyema?

Retrospective Study

Co – Investigator

Approved Ethics Committee : 05/09/2011 Nr. 3386/2011

(Published):

2012

The impact of lung cancer on survival of Idiopathic Pulmonary Fibrosis

Retrospective Study

Co – Investigator

Approved Ethics Committee : 26/08/2012 Nr. 2611/2012

(Published)

2012 The diagnostic role of Cryobiopsy in the multidisciplinary diagnosis of fibrotic interstitial lung diseases

Retrospective Study in two steps. Phase one: safety and feasibility. Phase two: MDD.

Principal Investigator

Approved Ethics Committee : 27/06/2013 Nr. 3106/2012

(Phase I: published; Phase II :published)

- 2013 Clinical and prognostic significance of circulating autoantibodies in Idiopathic Pulmonary Fibrosis
Retrospective Study
- Principal Investigator**
Approved by Ethics Committee
- Sleeping Disorders in IPF (DRS in IPF)
- 2014 Prospective
—
Co-PI
The purpose of this prospective study is to investigate clinical and physiopathological aspects of sleeping disorders of IPF.
Approved by Ethics Committee
Published
- 2015 Chest US post criobiopsy for the detection pf PNX
Prospective
PI
The purpose is to investiget the role of transthoracic echography in detection of early postprocedural PNX
Approved by EC
Published

Report of Invited Presentations

Regional

- 15-16 Sept 2006 Clinical Case - Lymphoproliferative Lung Disorders
Ematologo e Pneumologo Congress – GB Morgagni Hospital, Forlì, ITALY
- 26-27 Jun 2007 Lung Lymphoproliferative Disorders
Pneumopatie infettive e pseudoinfettive. GB Morgagni Hospital, Forlì Giugno ITALY
- 13 Nov 2007 Lymphoproliferative disorders: the role of pulmonologist
Stage in Ematologia: linfomi polmonari, i progressi della conoscenza. Università Studi di Bologna, Bologna ITALY
- 27-28 Nov 2007 Idiopathic Pulmonary Fibrosis

	Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
4-8 Feb 2008	Idiopathic Pulmonary Fibrosis
	Corso residenziale. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
26-27 Jun 2008	Lung Lymphoproliferative Disorders
	Pneumopatie infettive e pseudoinfettive. GB Morgagni Hospital, Forlì Giugno ITALY
15-19 Sep 2008	Idiopathic Pulmonary Fibrosis
	Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
25-27 Jan 2010	Idiopathic Pulmonary Fibrosis
	Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
18 May 2010	Oxygen therapy in IPF
	Corso teorico-pratico. Hospice, Forlimpopoli, ITALY
14-16 June 2010	Idiopathic Pulmonary Fibrosis
	Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
13-15 Dec 2010	Idiopathic Pulmonary Fibrosis, Corso teorico-pratico. Interstiziopatie polmonari. GB Morgagni Hospital, Forlì ITALY
1 Dec 2010	Clinical case of Sarcoidosis
	Le Malattie Rare del Polmone. Modena Univeristy, Modena, Forlì ITALY
16 Dec 2010	Therapeutic approaches of Idiopathic Pulmonary Fibrosis
	RIPID workshop. Fibrosi ed ipertensione polmonare. GB Morgagni Hospital, Forlì ITALY
28-29 Feb 2012	1) La clinica della IPF, 2) La terapia della IPF.
	Corso: La Fibrosi Polmonare Idiopatica. GB Morgagni Hospital, Forlì ITALY
5-7 March 2012	1) La Fibrosi polmonare Idiopatica 3) Le vasculiti
	Corso: Le Pneumopatie infiltrative diffuse. GB Morgagni Hospital, Forlì ITALY
30 October, 2012	Corso : La Fibrosi Polmonare. GB Morgagni Hospital, Forlì ITALY

19-20 Feb, 2013 1) La clinica della IPF
 2) La terapia della IPF

Corso: La Fibrosi Polmonare Idiopatica. GB Morgagni Hospital, Forlì ITALY

20-22 March,
2013 1) La Fibrosi polmonare Idiopatica

Corso: Le Pneumopatie infiltrative diffuse. GB Morgagni Hospital, Forlì ITALY

10-12 April, 2013 1) La clinica della IPF
 2) La terapia della IPF

Corso: le Pneumopatie Infiltrative Diffuse. GB Morgagni Hospital, Forlì ITALY

9 Dec 2013 La Fibrosi polmonare Idiopatica Corso Speed-it. GB Morgagni Hospital, Forlì ITALY

24 Jan 2014 Diagnosis and treatment of DPLDs. Corso Insuff Respiratoria. Museo Internazionale delle ceramiche, Faenza, ITALY.

27-28 March 2014 IPF, Clinical Ceses presentation. CSI in IPF, Cube Hotel, Ravenna, ITALY.

Clinica della IPF

3-4 Feb, 2015 Corso IPF, Forlì, IT

Clinica della IPF;

3-5 March, 2015 Corso PID, Forlì, IT

PID

10 April, 2015 AIPO giovani, Bologna, IT

5-6 June, 2015 "L'imaging come guida alle procedure endoscopiche";

AIPO Pneumo Interventistica; Bologna, IT

13 June, 2015 "New mini invasive diagnostic techniques"; MAR, Modena, IT

15-17 June, 2015 "IPF clinica"; Cosro AIPO PID, Forlì, IT

8-9 Sept, 2015 "A future view on ILD" and "The MDD in ILD diagnosis";
Cryobiopsy meeting second ed., Ravenna, IT

18 Sept, 2015 "Clinical case"; Convegno nazionale SIRM , Parma , IT

9-11 Feb, 2016 "Clinica della IPF e dintorni"
Fibrosi Polmonare Idiopatica. Forlì, FC, IT

9-10 June
2014 The role of TBLC in MD diagnosis of IPF. Transbronchial lung cryobiopsy. ERS endorsed course. Ravenna, Italy

7-9 June, 2016 "Fibrosi polmonare idiopatica:clinica" e "Procedure diagnostiche invasive"
Corso Pneumopatie infiltrative diffuse. GB Morgagni H, Forlì, FC, IT

3-4 and 24-25 May, 2016 In Hospital Meeting: IPF Excellence. Forlì IT

- 3 May, "Il profilo clinico della IPF"
- 4 May "La terapia della IPF"
- 25 May "La criobiopsia polmonare"

28-19 Oct, 2016 "Treatment of IPF : an update"
TBLC in DPLD. Endorsed by ERS. Ravenna, IT

21 Oct, 2016 Meet the Expert in IPF. Forlì, FC, IT

- "Opzioni terapeutiche nel trattamento dell'IPF"
- "Casi clinici multidisciplinari: dalla diagnosi alla cura del paziente con IPF – Esperienze a confronto"

- “Stars e Black Holes: successi e problematiche irrisolte dei Centri di riferimento. Modelli e risultati organizzativi dei Centri e problematiche gestionali”

19 Oct, 2016 “Ottimizzare la gestione del paziente con BPCO” ECM 38-164989. Forlì, Italy

3 Nov, 2016 “La visione del clinico”

“FARMACISTI A CONFRONTO: APPROPRIATEZZA TERAPEUTICA, BUDGET DI SPESA E GESTIONE DELLE GARE” Rimini, IT

13-14 Dec, 2016 “La diagnosi differenziale”

LA CONDIVISIONE DELLA PRATICA CLINICA NELLA FIBROSI POLMONARE IDIOPATICA. 9 national centres web-connected. Forlì, IT.

14-16 Feb, 2017 “Profili clinici IPF e quasi IPF” and “Early IPF and IPF friends perchè e quando trattare”

Course: IPF and friends. Forlì, IT

30 Aprile, 2017 “PID: approccio diagnostico”

Course: XIV corso teorico-pratico Pneumologia Interventistica, Parma, IT

8-9 Maggio, 2017 Lectures:

- “Opzioni terapeutiche”
- “Aspetti organizzativi nella gestione del paziente” Tavola rotonda

Course: Clinical management of IPF, Ravenna, IT

20-21 June, 2017 Lecture: “IPF” and Chair of the session “Patologia sistematica I”

Course: Pneumopatie infiltrative diffuse, Forlì, IT

24 Sept, 2017 Lecture: “ILDs, la gestione del paziente in Italia: differenze tra teoria e pratica clinica”

Course: Respirare e Comunicare, Forlì, IT

9-10 Nov, 2017 Lecture: “Novità dai congressi internazionali: aspetti clinici”

Course: IPF in Practice personalizzare l’algoritmo terapeutico, Ravenna, IT

1-2 Feb, 2018 Lecture: “IPF e tumore polmonare: modalità di gestione dell’esperienza clinica”

IPF Connect, Ancona, IT

15-16 March, 2018 Lectures:

- “La gestione del paziente acuto”
- “La terapia di IPF e quadri IPF”
- “IPF e quasi IPF”

Course: Respirare e comunicare, Forlì, IT

Teaching Experience in Educational Programs

3-5 June 2014	Perceptorship. International training program for chest physicians on IPF sponsored by Intermune. GB Morgagni Hospital, Forlì, Italy
13-15 Oct 2014	INSIDE IPF. National training program for chest physicians on IPF sponsored by Intermune. GB Morgagni Hospital, Forlì, Italy
20-2 Oct 2014	Perceptorship. International training program for chest physicians on IPF sponsored by Intermune. GB Morgagni Hospital, Forlì, Italy
11-12 Nov, 2014	Global internal train the trainer meeting, for pharma industry representatives, sponsored by Boeringher-Inghelheim. Frankfurt, Germany.
Nov-Dec, 2015	“In-Hospital” and “Tutorship” programs, for pharma industry representatives sponsored by Boeringher-Inghelheim, GB Morgagni Hospital, Forlì, IT.
4 Nov 2015	“Regional Lab”, Forlì, FC, IT. Educational program for pharmacists sponsored by Boeringher-Inghelheim
15 Dec, 2015	“Call Simulation”, Educational program for pharmacists sponsored by Boeringher- Inghelheim Bologna, IT
12-14 Jan, 2016	“In-Hospital” program for pharma industry representatives sponsored by Boeringher- Inghelheim, GB Morgagni Hospital, Forlì, IT.
23-25 Nov, 2016	Perceptorship. International training program for chest physicians on IPF sponsored by Roche. GB Morgagni Hospital, Forlì, Italy

National

- 20-22 Oct 2008 Usual Interstitial Pneumonia
 Advanced Course. HRCT of the thorax. Arezzo, ITALY
- 1) Idiopathic Pulmonary Fibrosis
 2) Anti TNF treatment for ILDs-related to connective tissue diseases.
 3) Birt Hogg Dubè Syndrome
- 2-5 Dec 2009 AIPO National Pulmonary Congress, Milan Convention Center, ITALY
- 19 June 2009 Diagnosis of ILDs
 Aggiornamenti in Med Interna. Bari, ITALY
 1) Clinical profile of diseases with HRCT Reticular Patterns
 15-17 April 2010 2) Clinical Cases
- Corso teorico-pratico. Interstiziopatie polmonari. Gubbio, ITALY
- 10-12 May 2010 Idiopathic Pulmonary Fibrosis
 ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
- 25-26 Nov 2010 Birt Hogg Dubè Syndrome, the pulmonologist point of view
 Giornata di Informazione sulla sindrome di Birt Hogg Dubè. Az Osp S Croce Carle, Cuneo, ITALY
- 4-6 April 2011 Practical approaches to Idiopathic Pulmonary Fibrosis
 ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
- 30Nov-3Dec 2011 Evoluzione e storia naturale delle pneumopatie interstiziali - IPF e cancro
 XII National Congress UIP, Bologna, ITALY
- 26-28 March, 2012 Clinical differential aspects of IPF.
 ERS course at PneumoTrieste Annual Meeting, Trieste, ITALY
- 12-14 April, 2012 Fibrosi Polmonare Idiopatica : la clinica.
 Le pneumopatie infiltrative diffuse: nuove acquisizioni. Villanovaforru, Cagliari.

- 3-5 May 2012 Le PID con pattern reticolare
III post graduate course: le PID conoscere per riconoscere. Gubbio, Italy.
- 26-27 Oct, 2012 Pirfenidone Named Patient Program.
AIR Meeting Italia. Rome, Italy.
- 8-10 April, 2013 Different clinical profiles of IPF.
ERS course at PneumoTrieste Annual Meeting, Trieste, ITALY
- 17 April, 2013 La clinica delle interstiziopatie polmonari.
Corso di patologia pleuro-polmonare. Dipartimento Anatomia Patologica, Università degli Studi di Verona, Italy.
- 27 April, 2013 Criobiopsia
Sorrento Breathing, Sorrento, Italy.
- 7-9 Maggio, 2013 La IPF: la clinica
Pneumopatie infiltrative diffuse, asma e BPCO. Villanovaforru, Cagliari, ITALY
- 28-29 June, 2013 L'esperienza NPP in Italia: cosa abbiamo imparato.
AIR MEETING ITALIA 2013. Milano, Italy.
- 7-9 April 2014 Idiopathic Pulmonary Fibrosis, clinical aspects
ERS scientific group on DPLD post graduate course, PneumoTrieste, Trieste, ITALY
- 7-8 June 2014 Novel Therapies for IPF. Asthma, IPF and other ILDs. Assisi, ITALY
- 27-28 June, 2014 IPF, mystery case
AIR MEETING ITALIA 2014. Rome, Italy.

- 1-3 oct, 2014 Update on ILD
FIP, National Pulmonology Congress, Genova, Italy.
- 8-11 Sept ,2014 La clinica delle interstiziopatie polmonari.
PneumoCampania 2014 - 7[^] edizione Vietri sul Mare, Italy.
- 23-25 Oct 2014 Clinical cases on ILDs
III post graduate course: le PID conoscere per riconoscere. Gubbio, Italy.
- 28-29Nov, 2014 “Clinica e terapia della IPF;” Updates in Pneumologia, Cosenza, Italy
- 5-6 Nov, 2014 Staging e FU della IPF, IPF workshop, Palermo, Italy
- 7-8 Nov, 2014 “IPF aspetti clinici e terapeutici”; Convegno interregionale ASPAM Terni, IT
- 14-15 Nov,2014 “Diagnosi della IPF con tecniche invasive”; AIPO Toscana, Massa Carrara, IT
- 5-6 Feb 2015 “Le metodiche invasive”; Orizzonti in pneumologia, Verona, IT
- 13-15 April 2015 “PPFE, NSIP, HP”; Pneumotrieste 2015, Trieste, IT
- 9 May, 2015 “Grande fornitore di UIP”; 20anni di trapianto, Padova, IT
- 29-30 May, 2015 “DIAGNOSIS OF PULMONARY FIBROSIS, WHAT’S NEW?”,
the Missing Links, Roma, IT
- 25-26 June, 2015 “End point dei trial clinici nella IPF, cosa migliorare”; Air meeting Italia, Roma, IT
- 2 Oct, 2015 “Clinical case”; LA DIAGNOSI MULTIDISCIPLINARE E LE SCELTE TERAPEUTICHE
DELLE PID e IPF; Firenze, IT
- 9-10 Oct, “IPF:an heterogeneous entity”; AIPO Lazio, Nemi, Roma, IT
- 16-17 Oct, “IPF profile clinic e stadiazione”; IPF next generation, Matera, IT
- 19 Oct, 2015 “IPF”; Confidence, Trieste, IT

6 Nov, 2015 "I misteri delle malattie dell'interstizio polmonare ed i segreti del ventricolo destro"
San Daniele del Friuli, Udine, IT

11-15 Nov, 2015 AIPO, Annual National Congress. Naples, IT:

- 12 Nov, "Highlights dalle recenti linee guida/raccomandazioni nazionali ed internazionali"
- 13 Nov, "Common Variable Immunodeficiency"
- 14 Nov, "IPF treatment"

11, Dec 2015 "Biopsia per via endoscopica o chirurgica?"
Pneumoroma Annual Congress. Roma, IT

12, Dec 2015 "UIP il punto sul Pirfenidone e le nuove terapie"
Updates in Pneumologia. Mendicino, CS, IT

21—22 Jan, 2016 "La fibrosi polmonare idiopatica: patogenesi e terapia"
Bari Pneumologica. Bari, IT

18-20 Feb, 2016 "Lo Pneumologo: il nuovo documento AIPO-SIMeR"
Il futuro della pneumologia...la pneumologia del future. Lecce, IT

12-13 April, 2016 "New frontiers. Early IPF"
ERS course DPLD. Respiro Trieste. Trieste, IT

14-15 April, 2016 "La terapia medica della fibrosi polmonare idiopatica: passato, presente e futuro"
Aggiornamento sulle patologie polmonari. Taranto, IT

16 April, 2016 "Biomarkers: quale utilità ai fini diagnostici, prognostici e di risposta alle terapie"
Innovazione ed organizzazione in pneumologia. Matera, IT

20 April, 2016 "Attualità in tema di IPF"
Congresso sez regionale AIPO ER. Baggiovara, Modena, IT

28-30 April, 2016 "Le Infezioni disseminate"
Le pneumopatie interstiziali diffuse. Gubbio, IT

6 May, 2016 "Dagli elementi anatomo-patologici all'Imaging. Quali certezze per il clinico?"
Col fiato corto 6. Palermo, IT

27 May, 2016 "Fibrosi e granulomatosi polmonare da droghe"
11° Pneumosalento. Lecce, IT

17-18 June, 2016 "Terapia dell'IPF"

La criobiopsia nella patologia parenchimale diffusa. Genova, IT

23-25 June, 2016 "I marcatori di patologia nell'IPF: molecolari, funzionali, clinico-radiologici"

AIR Meeting National. Baveno, IT

7-8 Oct, 2016 "La gestione diagnostica dei casi "difficili" e il ricorso alla biopsia: quando è necessaria una diagnosi istologica e come eseguirla".

Le pneumopatie infiltrative diffuse. Chieti, IT

8 Nov, 2016 "Criobiopsia"

La patologia toracica di interesse chirurgico e medico: le convergenze parallele. Verona, IT

11 Nov, 2016 "Nuove linee guida nazionali ed internazionali della IPF: similitudini differenze"

AIPO regione Marche. Civitanova Marche, IT

15-17 Dec, 2016 "Markers molecolari della IPF e dei suoi mimickers"

Pneumoroma. Roma, IT

2-3 Jan, 2017 "La terapia della NSIP"

Orizzonti in Pneumologia. Verona, IT

31 March-1 April, 2017 Il trattamento «ritardato» nell'IPF è ancora accettabile? Oxford Debate

AIR Meeting Italy, Bologna, IT

3-5 April, 2017 "ILA prevalence and clinical relevance"

ERS course DPLD. Respiro Trieste. Trieste, IT

10 e 31 May, 2017 speaker and tutor Sliding Doors course for pulmonologists, Padova, IT

26-27 May, 2017 Speaker: "La criobiopsia nella diagnosi delle PID"

S.S.D.PNEUMOLOGIA Settore Aggiornamento e Formazione
INTERNATIONAL CONGRESS, Courmayeur, Aosta IT

10-13 June, 2017 Speaker: "PID Acute" 12 June

Chair: "Granulomatosi polmonari" 13 june
AIGO, National Congress of Italian Pulmonology, Bologna, IT

16-17 June, 2017 Speaker: "Pattern fibrosante: quando è IPF", and clinical cases presentation
Fibrosing lung diseases a MD approach, Ancona , IT

4- Nov, 2017 Lectures:

- "Meccanismi patogenetici e correlazioni radiologiche e patologiche"
- "Il profilo della early IPF"

Course: La fibrosis polmonare idiopatica, Brindisi , IT

Report of Invited Presentations

International

24 May 2012 Genetic determinants of Familial Pulmonary Fibrosis.

Developmental Pulmonology Laboratory Research Conference. Department of Pediatrics, S Francisco General Hospital, UCSF, CA, USA.

30Nov-1Dec, 2012 Interactive Clinical Cases. Working together to translate IPF research into practice.
European AIR Meeting, Rome, Italy.

5 June 2013 The role of TBLC in the multidisciplinary diagnosis of IPF.

Wasog Meeting. Paris, France*

***Recipient of the Wasog Best Poster Presentation Award**

19-21 June 2014 The pathogenesis of NSIP.

Fibrosing Interstitial Lung Dis of idiopathic and exogenous origin. Prague, Czech Rep.

- 6-10 Sept 2014 Patient cases: the multidisciplinary approach
 Evening Symposium : How to diagnose and treat IPF: learnings from clinical and real-world experience
 ERS annual congress. Munich. Germany
- 27 Sept, 2015 “Educational skills workshop: EW10 Radiological – pathological correlations for clinicians”; Workstation 2: Interstitial fibrosis;
 ERS annual Congress, Amsterdam, Netherlands
- 27 Nov, 2015 “MDT case in Session 2: Striving for early IPF diagnosis”
 Air Meeting International. Prague, CZ
- 12 March, 2016 Transbronchialcryobiopsy in ILD, overview and update
 presented with Prof. T.V. Colby, Mayo Clinic ,AZ
 USCAP Annual Meeting, Seattle, WA, USA
- 16 March, 2016 Transbronchialcryobiopsy in ILD, overview and update
 Pulmonary Fellow Wednesday Morning Meeting, Mayo Clinic ,AZ
- 16 March, 2016 Transbronchialcryobiopsy in ILD, overview and update
 Pulmonary Metting, Phoenix Hospital, AZ
- 8-11 May, 2016 “Multidisciplinary diagnosis”
 World Congress for Bronchology and Interventional Pulmonology. Florence, IT
- 1-4 June, 2016 8th international WASOG conference. Gdnask, Poland
 • Transbronchial cryobiopsy in diffuse parenchymal lung diseases
 • Case presentation clinical round
- 2-7 Sept 2016 ERS Annual Congress. London, UK
 • Skills workshop: SW20 Radiological-pathological correlations for clinicians. Workstation

2: Interstitial fibrosis

- Year in review: Clinical year in review Diffuse parenchymal lung disease. Session 518

17-19 Nov, 2016 “BLC for the diagnosis of IPF”

Advancing IPF Research (AIR) Educational Meeting. Vienna.

22 Feb, 2016 “Transbronchial lung cryobiopsy in idiopathic interstitial pneumonia: state of the art “

Workshop: a new era for IP. Leuven, Belgium

23 Feb, 2016 “Clinical diagnostic value of bronchoscopy in IIP “

Interventional Pulmonology symposium. Leuven, Belgium

9-13 Sept, 2017 Speaker and tutor: “Skills workshop: SW20 Radiological-pathological correlations for clinicians. Workstation 2: Interstitial fibrosis

ERS, Milan, IT

10-11 Oct, 2017 Speaker:

- “Cryo-TBB vs awakened VATS
- “IPF therapy : the future

Chair of the session: “Technical notes. TBCB: how should be done”

Course: Transbronchial cryobiopsy in DLPD “ endorsed by ERS, Ravenna, IT

15-18 Nov, 2017 Speaker: “Cryobiopsy and ILD”

17º Congresso paulista de Pneumologia e Tisiologia, sao Paulo, Brazil

14-15 Dec, 2017 Con debate: ““IPF should be viewed as a malignancy, based on pathogenesis, biomarker signal and disease behaviour”
International summit for ILD, ERICE study group, ERICE, IT

Most Relevant Activities at International Meetings (last 5 years).

Date and Location	Course/Activity
24-28 Sept, 2011	European Respiratory Society Annual Meeting Amsterdam, The Netherlands Co-chair for Thematic Poster Session entitled: Rare diffuse lung diseases.
19-23 May, 2012	ATS Annual Meeting, San Francisco, CA, USA, May 2012. Poster Presentation Abstract 30968 “Transbronchial biopsy is a useful mini-invasive sampling method to detect UIP pattern”.
1-5 Sept, 2012	European Respiratory Society Annual Meeting Co-chair for Poster Discussion Session: idiopathic pulmonary fibrosis.
7-11 September, 2013	European Respiratory Society Annual Meeting Co-chair Thematic Poster Session entitled: Diffuse parenchymal lung disease II Chair Poster Discussion Session entitled: Idiopathic pulmonary fibrosis and rarities
26-30 Sept, 2015	European Respiratory Society Annual Meeting 30/9/2015 Chair Poster Discussion entitled: New insight into IIPs 30/9/2015 Chair Oral Presentation entitled: IPF clinical aspects II
8-11 May, 2016	2016 World Congress for Bronchology and Interventional Pulmonology. Florence, IT Chair Poster Discussion session “Bronchoscopy in TB and diffuse lung diseases. BAL and cryo biopsy”
2-7 Sept 2016	ERS Annual Congress. London, UK coChair Thematic Poster: Clinical aspects of ILD T10 session 174
9-13 Sept, 2017	- Chair : Oral session “gastrointestinal diseases and lung” and Chair Thematic poster session “ILDs: clinical aspects”

ERS, Milan, IT

Report of Clinical Activities and Innovations

Current Licensure and Certification

1 June 2001 Italian Medical Licence, Bologna, Italy

Practice Activities				
2007-2014	IPF Clinic	Pulmonary Unit, Morgagni Hospital	GB One	Sessions per week
2015-currently	ILD Clinic (AIMART)	Pulmonary Unit, Morgagni Hospital	GB Three/four	Sessions per week
2007-2014	Outpatient general Pulmonary Unit, Pulmonary Clinic	Morgagni Hospital	GB Twentyfive	weeks per year
2007-2013	Inpatient General Pulmonary Unit, Pulmonary Clinic	Morgagni Hospital	GB Ten weeks	per year
2007-2013	Interventional Pulmonology	Pulmonary Unit, Morgagni Hospital	GB Ten weeks	per year
2015-currently	Interventional Pulmonology	Pulmonary Unit, Morgagni Hospital	GB One/two sessions	per week
2007-currently	On-call-Interventional Pulmonology	Pulmonary Unit, Morgagni Hospital	GB On call once/twice a week and one week-end per month	
2013-currently	On-call-General Pulmonology	Pulmonary Unit, Morgagni Hospital	GB On call once/twice a week and one week-end per month	

Clinical Innovations

IPF-database. In collaboration with Biomedical Engineer I have developed a database and collected the data of more than 700 IPF patients. The main goal was to create a

Pulmonary Unit; GB Morgagni Hospital (2005-2016) tool to convert electronic medical records into useful data for research purpose. The database has been used in our ILD clinic to collect all clinical data in a prospective manner and to effectively enroll patients in clinical trials. Data have been used for several studies (reported in publication section) and have been presented at national and international meetings.

Transbronchial Cryobiopsy for ILDs diagnosis
y Unit; GB Morgagni Hospital (2011- currently)

Medical Thoracoscopy
Pulmonary Unit; GB Morgagni Hospital (2007-2013)

EUS/EBUS; Pulmonary Unit; GB Morgagni Hospital (2007-2013) I have been trained in the use of transbronchial (extensive experience) and transesophageal (initial training) ultrasound. We have published several studies on these tools applications (see peer reviewed publications)

Report of Education of Patients and Service to the Community

AMMP Associazione Morgagni per le Malattie Polmonari
2009- currently

I am one of the founders and an active member of this organization that promotes information about lung health in the local community and supports research and educational programs in the field of rare lung disorders.

Organizer and promoter of the event entitled “Il rinforzo della trama”, educational activities dedicated to patient associations and local pulmonary physicians

14/09/2014 “ Il rinforzo della trama I ed”, Fratta Terme , FC, IT

25/10/2015 “ Il rinforzo della trama II ed”, Fratta Terme , FC, IT

12/3/2017 “ Il rinforzo della trama IIIed”, Fratta Terme , FC, IT

Report of Scholarship

Doctoral Thesis in Respiratory Medicine

2004 – Modena and Reggio Emilia University, Modena, ITALY

TITLE “A possible immunological role for dendritic cells in chronic obstructive lung disease pathogenesis: the antigen presentation process may be influenced by an impairment of their migratory ability caused by MMP12 and others MMPs/MMPs inhibitors expression imbalance”.

Principal Investigator: Prof. SD Shapiro, Respiratory and Critical Care Medicine, Harvard University, Boston, MA, USA

Chair: Prof. LM Fabbri, Respiratory Medicine, Modena and Reggio Emilia University, Modena, Italy

Peer reviewed publications in print or other media

Research investigations (*equal contribution)

1. Bosi M, Milioli G, Fanfulla F, **Tomassetti S**, Ryu JH, Parrino L, Riccardi S, Melpignano A, Vaudano AE, Ravaglia C, Tantallocco P, Rossi A, Poletti V. OSA and Prolonged Oxygen Desaturation During Sleep are Strong Predictors of Poor Outcome in IPF. *Lung*. 2017 Oct;195(5):643-651.
2. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, **Tomassetti S**, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *Eur Respir J*. 2017 Aug 31;50(2).
3. Ravaglia C, Wells AU, **Tomassetti S**, Dubini A, Cavazza A, Piciucchi S, Sverzellati N, Gurioli C, Gurioli C, Costabel U, Tantallocco P, Ryu JH, Chilosi M, Poletti V. Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and Complications. *Respiration*. 2017;93(4):285-292. doi: 10.1159/000456671. Epub 2017 Mar 1.

4. Viglietta L, Inchingolo R, Pavano C, Tomassetti S, Piciucchi S, Smargiassi A, Ravaglia C, Dubini A, Gurioli C, Gurioli C, Poletti V. Ultrasonography for the Diagnosis of Pneumothorax after Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases. *Respiration*. 2017;94(2):232-236.
5. Caliò A, Lever V, Rossi A, Gilioli E, Brunelli M, Dubini A, **Tomassetti S**, Piciucchi S, Nottegar A, Rossi G, Kambouchner M, Cancellieri A, Barbareschi M, Pelosi G, Doglioni C, Cavazza A, Carella R, Graziano P, Murer B, Poletti V, Chilosi M. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. *Histopathology*. 2017 May 30.
6. Mariani F, Gatti B, Rocca A, Bonifazi F, Cavazza A, Fanti S, **Tomassetti S**, Piciucchi S, Poletti V, Zompatori M. Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. *Diagn Interv Radiol*. 2016 Jul 26.
7. **Tomassetti S**, Wells AU, Costabel U, Cavazza A, Colby TV, Rossi G, Sverzellati N, Carloni A, Carretta E, Buccioli M, Tantocco P, Ravaglia C, Gurioli C, Dubini A, Piciucchi S, Ryu JH, Poletti V. Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*. 2016 Apr 1;193(7):745-52.
8. Ravaglia C, Bonifazi M, Wells AU, **Tomassetti S**, Gurioli C, Piciucchi S, Dubini A, Tantocco P, Sanna S, Negri E, Tramacere I, Ventura VA, Cavazza A, Rossi A, Chilosi M, La Vecchia C, Gasparini S, Poletti V. Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases: A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature. *Respiration*. 2016;91(3):215-27.
9. Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, **Tomassetti S**, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. *Respir Med*. 2015 Jul;109(7):904-13.
10. **Tomassetti S***, Gurioli C*, Ryu J, Decker P, Ravaglia C, Tantocco P, Buccioli M, Piciucchi S, Sverzellati N, Dubini A, Gavelli G, Chilosi M, Poletti V. The impact of lung cancer on survival of Idiopathic Pulmonary Fibrosis. *Chest*. 2015 Jan;147(1):157-64.
11. Ravaglia C, **Tomassetti S**, Gurioli Ch, Piciucchi S, Dubini A, Gurioli C, Casoni GL, Romagnoli M, Carloni A, Tantocco P, Buccioli M, Poletti V. Features and outcome of familial idiopathic pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis*. 2014 Apr 18;31(1):28-36.
12. GL Casoni*, S **Tomassetti***, A Cavazza, TV Colby, A Dubini, JH Ryu, E Carretta, P Tantocco, S Piciucchi, C Ravaglia, C Gurioli , M Romagnoli, C Gurioli , M Chilosi, V Poletti. Transbronchial Lung Cryobiopsy in The Diagnosis of Fibrotic Interstitial Lung Diseases *PLoS One*. 2014 Feb 28;9(2):e86716.
13. Chilosi M, Facchetti F, Caliò A, Zamò A, Brunelli M, Martignoni G, Rossi A, Montagna L, Piccoli P, Dubini A, Tironi A, **Tomassetti S**, Poletti V, Doglioni C. Oncogene induced senescence

- distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans' cell histiocytosis. *Leuk Lymphoma*. 2014 Jan 29.
14. Ulivi P, Casoni GL, Foschi G, Scarpi E, **Tomassetti S**, Romagnoli M, Ravaglia C, Mengozzi M, Zoli W, Poletti V. MMP-7 and free circulating DNA serum levels in early NSCLC and idiopathic interstitial pneumonia patients. *Int J Mol Sci*. 2013 Dec 11;14(12):24097-112.
 15. **S. Tomassetti**, J.H. Ryu, C. Gurioli, C. Ravaglia, M. Buccioli, P. Tantocco, P.A. Decker, A. Cavazza, A. Dubini, V. Agnoletti, C. Gurioli, G.L. Casoni, M. Romagnoli, V. Poletti The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice. *Sarcoidosis Vasc Diffuse Lung Dis*. 2013 Aug 1;30(2):121-127.
 16. Ravaglia C, **Tomassetti S**, Gurioli C, Buccioli M, Tantocco P, Derni S, Maltoni M, Poletti . Palliative medicine and end-of-life care in idiopathic pulmonary fibrosis. *J Palliat Med*. 2013 Apr;16(4):339.
 17. **Tomassetti S**, Cavazza A, Colby TV, Ryu JH, Nanni O, Scarpi E, Tantocco P, Buccioli M, Dubini A, Piciucchi S, Ravaglia C, Gurioli C, Casoni GL, Gurioli C, Romagnoli M, Poletti V. Transbronchial biopsy is useful in predicting UIP pattern. *Respir Res*. 2012 Oct 29;13:96
 18. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, **Tomassetti S**, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Ann Intern Med*. 2012 May 15;156(10):684-91.
 19. Piciucchi S, **Tomassetti S**, Casoni G, Sverzellati N, Carloni A, Dubini A, Gavelli G, Cavazza A, Chilosi M, Poletti V. High resolution CT and histological findings in idiopathic pleuroparenchymal fibroelastosis: features and differential diagnosis. *Respir Res*. 2011 Aug 23;12:111.
 20. Casoni GL, Cordeiro CR Jr, **Tomassetti S**, Romagnoli M, Chilosi M, Cancellieri A, Gurioli C, Poletti V. The transbronchial lung biopsy for diagnosis of diffuse parenchymal lung disease; *Rev Port Pneumol*. 2011 Jun 28.
 21. **Tomassetti S**, Carloni A, Chilosi M, Maffè A, Ungari S, Sverzellati N, Gurioli C, Casoni G, Romagnoli M, Gurioli C, Ravaglia C, Poletti V. Pulmonary features of Birt-Hogg-Dubé syndrome: cystic lesions and pulmonary histiocytoma. *Respir Med*. 2011 May;105(5):768-74. Epub 2011 Feb 26.
 22. Romagnoli M, Nannini C, Piciucchi S, Girelli F, Gurioli C, Casoni G, Ravaglia C, **Tomassetti S**, Gurioli C, Gavelli G, Carloni A, Dubini A, Cantini F, Chilosi M, Poletti V. Idiopathic NSIP: an interstitial lung disease associated with autoimmune disorders? *Eur Respir J*. 2011 Jan 27.
 23. Reghellin D, Poletti V, **Tomassetti S**, Dubini A, Cavazza A, Rossi G, Lestani M, Pedron S, Daniele I, Montagna L, Murer B, Chilos M. Cathepsin-K is a sensitive immunohistochemical marker for detection of micro-granulomas in hypersensitivity pneumonitis. *Sarcoidosis Vasc Diffuse Lung Dis*. 2010 Jul;27(1):57-63.
 24. Casoni GL, Ulivi P, Mercatali L, Chilosi M, **Tomassetti S**, Romagnoli M, Ravaglia C, Gurioli C, Gurioli C, Zoli W, Silvestrini R, Poletti V. Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. *Int J Biol Markers*. 2010 Oct-Dec;25(4):229-35.

25. Maffé A, Toschi B, Circo G, Giachino D, Giglio S, Rizzo A, Carloni A, Poletti V, **Tomassetti S**, Ginardi C, Ungari S, Genuardi M. Constitutional FLCN mutations in patients with suspected Birt-Hogg-Dubé syndrome ascertained for non-cutaneous manifestations. *Clin Genet.* 2010 Jun 7.
26. Sverzellati N, Wells AU, **Tomassetti S**, Desai SR, Copley SJ, Aziz ZA, Zompatori M, Chilosi M, Nicholson AG, Poletti V, Hansell DM. Biopsy proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin section CT diagnoses. *Radiology.* 2010 Mar;254(3):957-64
27. G Marchesini, M Brizi, G Bianchi, **S Tomassetti**, E Bugianesi, M Lenzi, S Natale, AJ McCullough, G. Forlani, N. Melchionda. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001; 50:1844-50

a. Other peer-reviewed publications (review, case reports and case series, report of new methods, guidelines and consensus documents)

28. **Tomassetti S**, Ravaglia C, Poletti V. Diffuse parenchymal lung disease. *Eur Respir Rev.* 2017 Apr 26;26(144).
29. Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, **Tomassetti S**, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagmeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V. Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. *Respiration.* 2018;95(3):188-200.
30. Colella S, Clementsen PF, Gurioli C, Gurioli CH, Ravaglia C, **Tomassetti S**, Rossi A, Piciucchi S, Dubini A, Poletti V. Endobronchial-ultrasound needle aspiration and endoscopic ultrasound-fine-needle aspiration in thoracic diseases. *Pathologica.* 2016 Jun;108(2):59-79.
31. Sverzellati N, Odore A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonizio G, Zompatori M, Dalpiaz G, Piciucchi S, Larici AR; Italian Structured Report on Fibrosing Lung Disease Consort. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. *Radiol Med.* 2018 Apr;123(4):245-253.
32. Poletti V, Ravaglia C, Dubini A, Piciucchi S, Rossi G, Kronborg-White S, **Tomassetti S**. How might transbronchial cryobiopsy improve diagnosis and treatment of diffuse parenchymal lung disease patients? *Expert Rev Respir Med.* 2017 Dec;11(12):913-917.
33. Bosi M, Ravaglia C, **Tomassetti S**, et al. La sindrome delle apnee ostruttive nel sonno nel paziente con stroke Rassegna vol 31 p 14-18 2016
34. **Tomassetti S**. Correva l'anno 2016. Rassegna Mal App Resp, 2016 in press

35. **Tomassetti S**, Ravaglia C, Poletti V. Diffuse parenchymal lung disease. Eur Resp Rev, 2016 in press
36. Piciucchi S, Dubini A, **Tomassetti S**, Sanna S, Ravaglia C, Carloni A, Gurioli C, Gurioli C, Colby TV, Poletti V. Angiosarcoma in the chest: radiologic-pathologic correlation: Case report. Medicine (Baltimore). 2016 Nov;95(48):e5348.
37. Piciucchi S, **Tomassetti S**, Colby TV, Poletti V. Role of fibrogenesis of gastroesophageal reflux and microaspiration in a patient with 12 years of radiologic follow-up. Hum Pathol. 2017 Jan;59:152-153.
38. Colby TV, **Tomassetti S**, Cavazza A, Dubini A, Poletti V. Transbronchial Cryobiopsy in Diffuse Lung Disease: Update for the Pathologist. Arch Pathol Lab Med. 2016 Sep 2.
39. Varone F, Mastrobattista A, Franchi P, Viglietta L, Poletti V, **Tomassetti S**, Dubini A, Tagliaboschi L, Calandriello L, Farchione A, Larici AR. Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone. Clin Respir J. 2016 Jun 20. doi: 10.1111/crj.12515.
40. Piciucchi S, **Tomassetti S**, Ravaglia C, Gurioli C, Gurioli C, Dubini A, Carloni A, Chilosi M, Colby TV, Poletti V. From "traction bronchiectasis" to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology? BMC Pulm Med. 2016 May 23;16(1):87.
41. **Tomassetti S**, Ryu JH, Piciucchi S, Chilosi M, Poletti V. Nonspecific Interstitial Pneumonia: What Is the Optimal Approach to Management? Semin Respir Crit Care Med. 2016 Jun;37(3):378-94.
42. Poletti V, Ravaglia C, Gurioli C, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Rossi A, **Tomassetti S**. Invasive diagnostic techniques in idiopathic interstitial pneumonias. Respirology. 2016 Jan;21(1):44-50.
43. **Tomassetti S**, Ryu JH, Poletti V. Staging systems and disease severity assessment in interstitial lung diseases. Curr Opin Pulm Med. 2015 Sep;21(5):463-9.
44. Milioli G, Bosi M, Poletti V, **Tomassetti S**, Grassi A, Riccardi S, Terzano MG, Parrino L. Sleep and respiratory sleep disorders in idiopathic pulmonary fibrosis. Sleep Med Rev. 2016 Apr;26:57-63.
45. Poletti V, Ravaglia C, **Tomassetti S**. Transbronchial cryobiopsy in diffuse parenchymal lung diseases. Curr Opin Pulm Med. 2016 May;22(3):289-96.
46. **S Tomassetti**. Correva l'anno 2015, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2016
47. Pietrangelo V, Piciucchi S, **Tomassetti S**, Ravaglia C, Gurioli C, Gurioli C, Cavazza A, Dubini A, Poletti V. Diffuse Neuroendocrine Hyperplasia with Obliterative Bronchiolitis and Usual Interstitial Pneumonia: An Unusual "Headcheese Pattern" with Nodules. Lung. 2015 Oct 7. [Epub ahead of print]
48. Antoniou KM, **Tomassetti S**, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. Curr Opin Pulm Med. 2015 Nov;21(6):626-33.

49. **Tomassetti S**, Piciucchi S, Tantallocco P, Dubini A, Poletti V. The multidisciplinary approach in the diagnosis of idiopathic pulmonary fibrosis: a patient case-based review. Eur Respir Rev. 2015 Mar;24(135):69-77.
50. Piciucchi S, Dubini A, **Tomassetti S**, Casoni G, Ravaglia C, Poletti V. A case of amiodarone-induced acute fibrinous and organizing pneumonia mimicking mesothelioma. Am J Respir Crit Care Med. 2015 Jan 1;191(1):104-6.
51. **Sara Tomassetti**, Carlo Albera Domenico Aronne Marco Confalonieri Sergio Harari Maurizio Luisetti Venerino Poletti Luca Richeldi Paola Rottoli Cesare Saltini Carlo Vancheri Patrizio Vitulo. Alberto Pesci. Documento AIPO-SIMeR sulla IPF. Rassegna di Mal App Resp, 2015
52. **S Tomassetti**. Correva l'anno 2014, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2015
53. Poletti V, Ravaglia C, **Tomassetti S**. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2014 Oct;8(5):539-45.
54. V Poletti, GL Casoni, C Gurioli, JH Ryu, **S Tomassetti**. Lung cryobiopsies: a paradigm shift in diagnostic bronchoscopy? Respirology. 2014 Jul;19(5):645-54.
55. **S Tomassetti**. Correva l'anno 2013, pneumopatie infiltrative diffuse e patologia del circolo polmonare. Rassegna di Patologia dell'Apparato Respiratorio, 2014
56. KM. Antoniou, GA. Margaritopoulos, **Sara Tomassetti**, F Bonella, U. Costabel and V. Poletti. INTERSTITIAL LUNG DISEASE: Year In Review. Eur Respir Rev. 2014 Mar 1;23(131):40-54.
57. V Poletti, C Ravaglia, **S Tomassetti**, C Gurioli, G Casoni, S Asioli, A Dubini, S Piciucchi, M Chilosi Lymphoproliferative lung disorders: clinicopathologic aspects. Eur Respir Rev. 2013 Dec;22(130):427-36.
58. **S Tomassetti**, JH. Ryu, G Casoni, C Gurioli, C Ravaglia, M Buccioli, P Tantallocco, C. Gurioli M Romagnoli, V Poletti. Revisione critica delle Linee Guida ATS/ERS sulla fibrosi polmonare idiopatica (IPF). Critical revision of ATS / ERS Guidelines on idiopathic pulmonary fibrosis (IPF). Rassegna di Patologia dell'Apparato Respiratorio 2013; 28: 74-89
59. Poletti V, Ravaglia C, Buccioli M, Tantallocco P, Piciucchi S, Dubini A, Carloni A, Chilosi M, **Tomassetti S**. Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. Respiration. 2013;86(1):5-12.
60. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax. 2012 Nov;67(11):938-40.
61. Ravaglia C, Gurioli C, **Tomassetti S**, Casoni GL, Romagnoli M, Gurioli C, Agnoletti V, Poletti V. Is medical thoracoscopy efficient in the management of multiloculated and organized thoracic empyema?. Respiration. 2012;84(3):219-24.
62. J.H. Ryu, F. Maldonado and **S. Tomassetti** Idiopathic tracheopathies. Eur Respir Mon 2011. 54, 1–15.

63. Gurioli C, Ravaglia C, Romagnoli M, Casoni G, **Tomassetti S**, Nanni O, Poletti V EBUS-TBNA in mediastinal/hilar lymphadenopathies and/or masses: an Italian case series. *Clin Respir J.* 2012 Jan;6(1):3-8.
64. Casoni GL, Chilosi M, Romagnoli M, **Tomassetti S**, Poletti V. Another "chance" for interferon gamma 1b? *Sarcoidosis Vasc Diffuse Lung Dis.* 2011 Jul;28(1):79-80
65. Poletti V, Casoni G, Ravaglia C, Romagnoli M, **Tomassetti S**. Bronchoalveolar lavage. Technical notes. *Monaldi Arch Chest Dis.* 2011 Mar;75(1):42-3.
66. Gurioli C, Casoni GL, Gurioli C, **Tomassetti S**, Romagnoli M, Ravaglia C, Poletti V. Endobronchial ultrasound in Dieulafoy's disease of the bronchus: an additional application of EBUS. *Monaldi Arch Chest Dis.* 2010 Dec;73(4):166-8.
67. Chilosi M, **Tomassetti S**, Carloni A, Murer B. The pathologist's role in the diagnosis of idiopathic pulmonary fibrosis. *Pathologica.* 2010 Dec;102(6):443-52.
68. Ravaglia C, Gurioli C, Casoni G, Romagnoli M, **Tomassetti S**, Gurioli C, Corso RM, Poletti G, Dubini A, Marinou A, Poletti V. Diagnostic role of rapid on-site cytologic examination (ROSE) of broncho-alveolar lavage in ALI/ARDS. *Pathologica.* 2012 Apr;104(2):65-9.
69. Ryu JH, **Tomassetti S**, Maldonado F. Update on uncommon pleural effusions. *Respirology.* 2010 Nov 15.
70. Poletti V, **Tomassetti**. Ultrasound endoscopy (EBUS, EUS) as a sophisticated tool for morphological confirmation of sarcoidosis: do we need to find new answers for an old quest? *S. Sarcoidosis Vasc Diffuse Lung Dis.* 2010 Jul;27(1):5-6.
71. Chilosi M, Tomassetti S, Carloni A, Murer B. The pathologist's role in the diagnosis of idiopathic pulmonary fibrosis. *Pathologica.* 2010 Dec;102(6):443-52.
72. Casoni GL, **Tomassetti S**, Coffa A, Ravaglia C, Poletti V. Negative pressure pulmonary hemorrhage induced by a candy. *Am J Emerg Med.* 2010 Jan;28(1):112.
73. De Filippo, Ingegnoli A, Carloni A, Verardo E, Sverzellati N, Onniboni M, Corsi A, **Tomassetti S**, Mazzei M, Volterrani L, Poletti V, Zompatori M. Erdheim-Chester disease: clinical and radiological findings. *Diagnostic Radiology . Radiol Med.* 2009 Nov 14.
74. Romagnoli M, Bigliazzi C, Casoni GL, Chilosi M, Carloni A, Dubini A, Gurioli Ch, **Tomassetti S**, Gurioli C, Poletti V. "The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients". *Sarcoidosis, Vasculitis and Diffuse Lung Diseases*, 2008.
75. Zinzani PL, Poletti V, Zompatori M, Tani M, Spaggiari L, **Tomassetti S**, Broccoli A, Derenzini E, Baccarani M. Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. *Clin Lymphoma Myeloma.* 2007 Nov;7(9):566-72.

- **Letters to the Editor**

1. Ravaglia C, Gurioli C, Casoni GL, Romagnoli M, **Tomassetti S**, Gurioli C, Dubini A, Poletti V. Sarcoid-like lesion is a frequent benign cause of lymphadenopathy in neoplastic patients. *Eur Respir J.* 2013 Mar;41(3):754-5.

2. G.Marchesini,M.Brizi,G.Bianchi,**S.Tomassetti**,M.Zoli,N.Melchionda. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358:893-4

- **Books/Textbooks for the medical or scientific community**

1. Gurioli, **S. Tomassetti**, C. Gurioli Applicazioni dell'ecografia endobronchiale alla broncoscopia terapeutica C . In Poletti V . and C eron L. Diagnistica ed interventistica ultrasonografica endoscopica. Edizioni minerva Medica, 2014.
2. Poletti V, Zinzani PL, **Tomassetti S**, Chilosi M. Lymphoproliferative Lung Disorders. In : Costabel U, Du Bois RM, Egan JJ (Eds). Diffuse Parenchymal Lung Disease. Progr Respir Res, Basel, Karger 2007:307-322.

Research publications without named authorship


Clinton S. Robbins, Francesca Franco, Majd Mouded, Manuela Cernadas, Steven D. Shapiro (Tomassetti S cited in the Acknowledgments section). Cigarette Smoke Exposure Impairs Dendritic Cell Maturation and T Cell Proliferation in Thoracic Lymph Nodes of Mice. J Immunol. 2008 May 15; 180(10): 6623–6628.

Non-peer reviewed publications in print or other media

1. **Tomassetti S¹**, Ravaglia C¹, Gurioli C¹, Chiappalone G¹, Poletti V¹. Prognostic assessment in IPF. Shortness of Breath, 2015
2. **S. Tomassetti**. Il fumo di sigaretta e la fibrosi polmonare idiopatica [Cigarettes smoke and IPF]. In: Nuovi Orizzonti. Editor: AIPO Ricerche 2008.
3. **S Tomassetti**. Fibrosi polmonare Idiopatica: attuali e future prospettive terapeutiche. Lung Forum, Workbook di aggiornamento in pneumologia, Sept 2014

	Tutte	Dal 2013
<u>Citazioni</u>	5285	2828

	Tutte	Dal 2013
<u>Indice H</u>	25	23
i10-index	38	36



* Google Scholar 18 March 2018

Narrative Report (limit to 500 words)

My major interest embrace both clinical and research activities in the field of rare lung diseases. During my four years of Residency in Pulmonary Medicine at Modena University, supervisor Prof. LM Fabbri, I have completed one year of research fellowship with Prof. SD Shapiro at Harvard University, Boston, MA, USA with a study focusing on the role of dendritic cells in chronic obstructive pulmonary disease. Back in Italy I have continued to work in Forlì, a referral centre for ILDs and interventional pulmonology. In the field of clinical research I have participated as sub-investigator and, more recently as principal investigator, in several clinical trials for IPF treatment and I have conducted numerous non-funded studies focusing on different clinical aspects of IPF. Since 2008 I have been participating for one month every year in the Mayo Clinic Visiting Clinician Program. This experience offered me a unique opportunity to improve my research and clinical skills. In 2005 I joined the staff of the Pulmonary Unit of GB Morgagni hospital, Forlì, Italy, as research fellow and in 2007 I obtained a permanent position in the staff. My clinical responsibilities included working as consultant pulmonary physician in both inpatients and outpatients service. More recently I'm focusing on outpatient service for ILD, currently I dedicate 70% of my clinical time following ILD patient in the outpatient clinic. I have lead the former IPF Clinic (one session per week) and I am currently leading the ILD Clinic AIMART (ILDs, rare diseases and lung transplant) (three session per week). I have worked for nearly ten years in Forlì that is one of the national referral centers for interventional pulmonology and I have been on-call for both general and interventional pulmonology. I currently dedicate 30% of my clinical time to interventional pulmonology.

My areas of expertise are interventional pulmonology (including rigid bronchoscopy and medical thoracoscopy), interstitial lung disorders and lung transplant, although our hospital is not a transplant centre. My current major clinical responsibility is to lead the ILD clinic and clinical research in this field. I have followed more than 500 patients afflicted by IPF. I have organized a clinical service that integrates research in real life practice. I have prospectively collected patients' data in one of the largest national IPF database and I am currently working on implementation of database and biobank. An expert radiologist is collaborating in this project reporting a detailed radiologic score for each case both at diagnosis and follow-up. One biomedical engineer follows the data-entry process. In collaboration with Prof. JH Ryu, Mayo Clinic, Rochester, MN, USA I had the opportunity to use the database in several original research as reported in the unfunded project section and in the scholarship report of publications. I have collaborated with top level international Institutions including: University of California S Francisco and Mayo Clinic, Rochester in the project entitled Staging system for IPF [Annals of Internal Medicine, 2012]; Mayo Clinic in numerous projects: Primary Pulmonary carcinoma and IPF [Chest 2014]; The role of transbronchial biopsy in UIP detection [Respiratory Research 2012]; Clinical impact of autoimmunity testing in IPF (in preparation); Transbronchial cryobiopsy in the diagnosis of IPF [PLOSOne, 2014]. I am currently working as PI of a multicenter study with Prof. AU Wells, Brompton Hospital, London, UK, Prof. U. Costabel, Hessen, Germany, Prof. TVColby Mayo Clinic, AZ, USA, Dr. N Sverzellati, Parma University, Italy, Dr. A Cavazza, Reggio Emilia University Italy, in a study investigating the impact of transbronchial cryobiopsy in the multidisciplinary diagnosis of fibrotic ILDs[AJRCCM, submitted].

My goal for the future is to have the chance to continue further research about pathogenic, clinical and therapeutic aspects of rare diseases, particularly focusing on IPF. My hope is to use the clinical and research knowledge acquired in these years of creation and implementation of the IPF Italian database to create a large collaborative network of international experts. The idea is to collaborate with other countries in order to implement the net of experts collaborating in this field, to achieve better scientific knowledge and improve the current standard of care of IPF and other rare lung diseases.



ENGLISH LANGUAGE PROFICIENCY CERTIFICATES**IELST**BRITISH COUNCIL, Bologna, 18th January 2014

Candidate Number 11435; Passport Number AA2422927

Results: LISTENING 8.0; READING 8.5; WRITING 7; SPEAKING 7; OVERALL 7.5.